News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-23 pm EDT			5-day change	1st Jan Change
29.17 ^USD	+1.11%		+0.66%	-5.29%

12:50am	Nordic stocks in North America, Ericsson fell 0.7%	FW
Jul. 23	Stocks to Watch : Intel, Deckers, Edwards Lifesciences, Genmab	DJ

All News

Mentions Relevance

Jul. 23	Stocks to Watch : Intel, Deckers, Edwards Lifesciences, Genmab	DJ
Jul. 23	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
Jul. 22	TD Cowen Upgrades Genmab to Buy Rating, Boosts PT	MT
Jul. 22	TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32	MT
Jul. 22	TD Cowen upgrades Genmab to buy (hold) - BN	FW
Jul. 21	Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN	FW
Jul. 15	Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales	MT
Jul. 15	Genmab's Darzalex sales totaled $4,207m in the second quarter	FW
Jul. 15	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026	GL
Jul. 07	Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma	MT
Jul. 07	Genmab rebounds on a European Commission decision
Jul. 07	EU approves expanded use of Genmab's Tepkinly	FW
Jul. 06	Genmab Wins EU Approval for Follicular Lymphoma Treatment Combination	MT
Jul. 06	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	GL
Jul. 06	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	BU
Jul. 06	Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
Jul. 06	BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN	FW
Jun. 30	Genmab hit a Phase 3 endpoint with epcoritamab in lymphoma	FW
Jun. 29	Genmab Says Epcoritamab Combo Improves Progression-free Survival in Phase 3 Blood Cancer Study	MT
Jun. 29	Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial	MT
Jun. 29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	BU
Jun. 29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	GL
Jun. 29	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Demonstrating Statistically Significant Improvement in Progression-Free Survival	CI
Jun. 24	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT
Jun. 23	Genmab: Financing weighs now, pipeline pays later